MOLECULAR PARTNERS AG (MOLN): Price and Financial Metrics


MOLECULAR PARTNERS AG (MOLN): $7.22

0.14 (+1.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MOLN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MOLN Stock Price Chart Interactive Chart >

Price chart for MOLN

MOLN Price/Volume Stats

Current price $7.22 52-week high $32.04
Prev. close $7.08 52-week low $5.92
Day low $7.02 Volume 61,200
Day high $7.32 Avg. volume 41,046
50-day MA $15.57 Dividend yield N/A
200-day MA $19.01 Market Cap 234.66M

MOLECULAR PARTNERS AG (MOLN) Company Bio


Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials.


MOLN Latest News Stream


Event/Time News Detail
Loading, please wait...

MOLN Latest Social Stream


Loading social stream, please wait...

View Full MOLN Social Stream

Latest MOLN News From Around the Web

Below are the latest news stories about Molecular Partners Ag that investors may wish to consider to help them evaluate MOLN as an investment opportunity.

Molecular Partners to Present at Upcoming Healthcare Investor Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022. The presentation will take place on Wednesday, February 16, at 9:20 am ET. The webcasted prese

Yahoo | February 11, 2022

Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19

Molecular Partners AG (NASDAQ: MOLN) and its partner Novartis AG (NYSE: NVS), have requested FDA Emergency Use Authorization (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. This submission is based on the totality of the data from clinical and preclinical studies, including the results of the Phase 2 portion of the EMPATHY study, which enrolled 407 symptomatic COVID-19 patients. Related: Novartis To In-License COVID-19 Treatment From Molecular Partners, After Enc

Yahoo | February 10, 2022

Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, was informed by its partner Novartis that the company has requested Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for ensovibep, a DARPin antiviral therapeutic candidate

Yahoo | February 10, 2022

3 Stocks That Have Soared as the Market Sank: Are They Buys Now?

It's hard for any stock to deliver positive gains while the market is falling. Molecular Partners' (NASDAQ: MOLN) shares have skyrocketed more than 40% year to date. On Jan. 10, Molecular Partners and Novartis announced positive results from their Empathy phase 2 study of ensovibep in treating acute COVID-19 patients.

Yahoo | January 28, 2022

Novartis Hopes to Have Another COVID Therapy on the Way

Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.

Yahoo | January 23, 2022

Read More 'MOLN' Stories Here

MOLN Price Returns

1-mo N/A
3-mo N/A
6-mo -39.12%
1-year N/A
3-year N/A
5-year N/A
YTD -62.36%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4878 seconds.